Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2018

Visual Acuity Outcomes in Patients With Persistent DME Receiving Adjunctive Therapy

Show Description +

Raj K. Maturi, MD, reviews the key points of a short-term study on the effect of adding dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) to continued ranibizumab (Lucentis, Genentech) treatment in patients with persistent diabetic macular edema (DME).

Posted: 7/21/2018

Up Next


OCT-A in Pediatric Patients

Lejla Vajzovic, MD

Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS

The Future of Global Trends in Retina

Ehab N. El Rayes, MD, PhD, Paul Hahn, MD, PhD

How Has the Value of Retinal Procedures Changed?

Pravin U. Dugel, MD, Timothy G. Murray, MD, MBA

Here's the DRIL

Amy Babiuch, MD

Women in Retina

Anne E. Fung, MD, Jennifer I. Lim, MD, Nancy M. Holekamp, MD

Surgical Repair of Macular Holes

Raymond Iezzi, MD, MS

The ASRS Takes Vancouver

Timothy G. Murray, MD, MBA

A Role for Biosimilars in Retina?

Alay S. Banker, MD, Charles C. Wykoff, MD, PhD, FACS

Visual Acuity Outcomes in Patients With Persistent DME Receiving Adjunctive Therapy

Raj K. Maturi, MD, reviews the key points of a short-term study on the effect of adding dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) to continued ranibizumab (Lucentis, Genentech) treatment in patients with persistent diabetic macular edema (DME).

Posted: 7/21/2018


Please log in to leave a comment.

More From ASRS: 2018 Coverage

A Role for Biosimilars in Retina?

Alay S. Banker, MD, Charles C. Wykoff, MD, PhD, FACS

OCT-A in Pediatric Patients

Lejla Vajzovic, MD

Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS